Observational studyEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2026
Discontinuation and nonpublication of osteosarcoma clinical trials: a cross-sectional analysis of ClinicalTrials.gov data.
Observational study in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Letter to the editor on: "Discontinuation and nonpublication of osteosarcoma clinical trials: a cross-sectional analysis of ClinicalTrials.gov data".European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma is a rare and aggressive malignancy with limited therapeutic advances despite extensive clinical research. Discontinuation and failure to publish trial results contribute to research waste and may delay progress in patient care. We aimed to characterize osteosarcoma clinical trials registered on ClinicalTrials.gov and evaluate factors associated with trial discontinuation and nonpublication.
methodsWe performed a cross-sectional analysis of interventional osteosarcoma trials registered on ClinicalTrials.gov as of July 1, 2025. Trial characteristics, including completion status, publication status, study design, funding source, trial phase, and enrollment size, were extracted. Multivariable logistic regression was performed to identify factors associated with trial discontinuation and nonpublication.
resultsAmong 210 eligible trials, 62 (29.5%) were discontinued before completion, and only 26 (17.6%) had published results. Smaller trials were more frequently discontinued and unpublished compared with larger trials. Multicenter trials demonstrated higher publication rates and were independently associated with lower odds of nonpublication (OR = 0.291, 95% CI 0.098-0.859; p = 0.025). No significant associations were observed between funding source, intervention type, or trial phase and trial outcomes.
conclusionsNearly one-third of osteosarcoma clinical trials are discontinued, and most completed trials lack published results, highlighting substantial research waste and limitations in evidence generation. Strengthening trial completion strategies, promoting multicenter collaboration, and improving transparency through mandatory results reporting may enhance the efficiency and impact of osteosarcoma research.
Indexed as
Identifiers
42573835What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.